Silence Therapeutics said it has named Max Herrmann as its new CFO.
Herrmann was most recently CFO of Intercytex, a public company focused on regenerative medicine. Before that, he spent 10 years as a sell-side equity analyst, most recently at ING. He also previously served as financial controller for Onyx Pharmaceuticals.
He holds a degree in microbiology from the University of Kent.
Biotech firm Taligen Therapeutics said that it has appointed Alnylam Pharmaceuticals CEO John Maraganore to its board of directors.
Before taking the helm of Alnylam, Maraganore was senior vice president of product development at Millennium Pharmaceuticals. He has also held roles at Biogen (now Biogen Idec) and Angiomax.